→
Previous
Latest
SR-76, As Adopted by Senate, October 8, 2025 SENATE RESOLUTION NO.
MICHIGAN SENATE Senate Resolution No.
76 Senators Anthony, Geiss and Polehanki offered the following resolution:
76 Offered by Senators Anthony, Geiss and Polehanki A RESOLUTION TO RECOGNIZE OCTOBER 2025 AS UTERINE FIBROIDS AWARENESS MONTH WHEREAS, Uterine fibroids, also known as leiomyomas or myomas, are non-cancerous growths that form in or around the uterus or pelvic cavity that can lead to significant pelvic pain, reproductive dysfunction, abnormal uterine bleeding, miscarriages, and infertility;
A resolution to recognize October 2025 as Uterine Fibroids Awareness Month.
and WHEREAS, Uterine fibroids can vary in number, size, and severity depending on the location and sometimes lead to distortion of the inside and outside of the uterus, or in some cases, can cause extreme pain when a fibroid outgrows its blood supply and starts to die, ultimately leading to more serious health complications;
Whereas, Uterine fibroids, also known as leiomyomas or myomas, are non-cancerous growths that form in or around the uterus or pelvic cavity that can lead to significant pelvic pain, reproductive dysfunction, abnormal uterine bleeding, miscarriages, and infertility;
and WHEREAS, The pain, discomfort, stress, and other physical and emotional symptoms of living with fibroids may interfere with a woman’s quality of life, affecting their personal and professional life, as well as their overall health and well-being;
and Whereas, Uterine fibroids can vary in number, size, and severity depending on the location and sometimes lead to distortion of the inside and outside of the uterus, or in some cases, can cause extreme pain when a fibroid outgrows its blood supply and starts to die, ultimately leading to more serious health complications;
and WHEREAS, Uterine fibroids are one of the most common medical conditions among women, with an estimated 26 million women in the United States (U.S.) impacted during their reproductive years, with the likelihood of developing the condition increasing with age;
and Uterine Fibroids_SR76_AA_1 naxj4d 1 Whereas, The pain, discomfort, stress, and other physical and emotional symptoms of living with fibroids may interfere with a woman’s quality of life, affecting their personal and professional life, as well as their overall health and well-being;
and WHEREAS, Despite their prevalence, statistics on uterine fibroids are often underestimated, as many women remain undiagnosed or do not seek medical care.
and Whereas, Uterine fibroids are one of the most common medical conditions among women, with an estimated 26 million women in the United States (U.S.) impacted during their reproductive years, with the likelihood of developing the condition increasing with age;
and Whereas, Despite their prevalence, statistics on uterine fibroids are often underestimated, as many women remain undiagnosed or do not seek medical care.
and Whereas, Uterine fibroids disproportionately impact women of color, as Black women are diagnosed with fibroids roughly three times as frequently as Caucasian women, with women of color being more prone to develop the condition earlier in life and tend to experience larger and more numerous fibroids that cause more severe symptoms;
and WHEREAS, Uterine fibroids disproportionately impact women of color, as Black women are diagnosed with fibroids roughly three times as frequently as Caucasian women, with women of color being more prone to develop the condition earlier in life and tend to experience larger and more numerous fibroids that cause more severe symptoms;
and Whereas, The diagnosis of fibroids starts with detection during a routine pelvic exam, but can lead to more complex testing, including a pelvic ultrasound, magnetic resonance imaging (MRI), hysterosalpingography, or hysteroscopy;
and WHEREAS, The diagnosis of fibroids starts with detection during a routine pelvic exam, but can lead to more complex testing, including a pelvic ultrasound, magnetic resonance imaging (MRI), hysterosalpingography, or hysteroscopy;
and Whereas, A woman’s fertility can be affected by uterine fibroids in a variety of ways, including the possibility of the fibroids growing and blocking the uterus or fallopian tubes, making it harder to become pregnant.
and WHEREAS, A woman’s fertility can be affected by uterine fibroids in a variety of ways, including the possibility of the fibroids growing and blocking the uterus or fallopian tubes, making it harder to become pregnant.
Other negative impacts include miscarriages, abnormal attachment of the placenta, increased likelihood of delivery by cesarean section, and postpartum Uterine Fibroids_SR76_AA_1 naxj4d 1 hemorrhage;
Other negative impacts include miscarriages, abnormal attachment of the placenta, increased likelihood of delivery by cesarean section, and postpartum hemorrhage;
and Whereas, Treatments for uterine fibroids range from medicinal to surgical approaches, depending on the severity of the case, symptoms, location and size of the fibroids, age, medical history, and a woman’s health goals.
and WHEREAS, Treatments for uterine fibroids range from medicinal to surgical approaches, depending on the severity of the case, symptoms, location and size of the fibroids, age, medical history, and a woman’s health goals.
Medicinal approaches include anti- inflammatory painkillers and hormonal treatments like oral contraceptive pills or progesterone-containing agents.
Medicinal approaches include anti-inflammatory painkillers and hormonal treatments like oral contraceptive pills or progesterone-containing agents.
and Whereas, A hysterectomy, defined as the surgical removal of the uterus, remains one of the most frequently performed procedures for the treatment of uterine fibroids.
and WHEREAS, A hysterectomy, defined as the surgical removal of the uterus, remains one of the most frequently performed procedures for the treatment of uterine fibroids.
and Whereas, The number of U.S.
and WHEREAS, The number of U.S.
and Whereas, A recent study showed the total annual economic burden of uterine fibroids in the U.S.
and WHEREAS, A recent study showed the total annual economic burden of uterine fibroids in the U.S.
is estimated at $42.2 billion, including direct medical costs, lost work productivity due to absenteeism and short-term disability among women ages 25–54, cesarean-related obstetrical expenses, and infertility-related treatment costs;
is estimated at $42.2 billion, including direct medical costs, lost work productivity due to absenteeism and short-term disability among women ages 25-54, cesarean-related obstetrical expenses, and infertility-related treatment costs;
and Whereas Public awareness and education about uterine fibroids is critical to increase knowledge about this condition and improve prevention, screening, diagnosis, and treatment methods;
and WHEREAS Public awareness and education about uterine fibroids is critical to increase knowledge about this condition and improve prevention, screening, diagnosis, and treatment methods;
now, therefore, be it Resolved by the Senate, That the members of this legislative Uterine Fibroids_SR76_AA_1 naxj4d body recognize October 2025 as Uterine Fibroids Awareness Month.
now, therefore, be it RESOLVED BY THE SENATE, That the members of this legislative body recognize October 2025 as Uterine Fibroids Awareness Month.
Uterine Fibroids_SR76_AA_1 naxj4d
Adopted by the Senate, October 8, 2025.
Secretary of the Senate
⬇ Download PDF